Meta AnalysisID 4016
拉替拉韦联合蛋白酶抑制剂简化方案在HIV-1患者中的疗效与安全性：一项随机对照试验的Meta分析
CRD42017082468
To evaluate the efficacy and safety on simplification approach of Raltegravir (RAL) combined with protease inhibitor for HIV-1 patients
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4016
- Evidence Id
- 12574
- Core Evidence Id
- 12574
- Source Meta Analysis Id
- 3975
- Herb2 Meta Analysis Id
- HBMA003975
- Crd Id
- CRD42017082468
- Title
- The efficacy and safety on simplification approach of Raltegravir combined with protease inhibitor in HIV-1 patients: a meta-analysis of RCTs
- Review Question
- To evaluate the efficacy and safety on simplification approach of Raltegravir (RAL) combined with protease inhibitor for HIV-1 patients
- Study Type Included
- We included RCT study with PIs combined with RAL verse PIs combined with NRTIs
- Condition Being Studied
- Raltegravir，HIV，simplification approach，efficacy and safety
- Participant
- Treated RAL with protease inhibitor (PIs) or PIs or 2/3NRTI. The HIV-1-infected patients with HIV RNA >400 copies/mL, and after treated, the HIV RNA <50 copies/mL
- Animal
- Human Disease Modelled
- Intervention
- In 2007, the US Food and Drug Administration (FDA) approved the Raltegravir (RAL) listing, becoming the first integrase inhibitor drug. It targeted the strand transfer reaction during the integration process. The drug has potent in vitro activity against strains of HIV-1 that are susceptible or resistant to other classes of antiretroviral drugs. Due to the efficacious and generally well tolerated nature of RAL in patients infected with human immunodeficiency virus type 1 (HIV-1), it is part of combination antiretroviral therapy. Currently, RAL combined with ritonavir-boosted protease inhibitor (PIs/r) has resulted in high levels of virological suppression in ARV-naïve and ARV-experienced HIV-1–infected patients.
- Comparator Control
- PIs combined with RAL verse PIs combined with NRTIs in this review.
- Main Outcome
- Plasma HIV-1 RNA viral load, CD4 cell counts and grade 3 or 4 adverse events between PIs, combined with RAL group, and PIs combined with NRTIs group
- Outcome Measure
- Additional Outcome
- Drug resistance between PIs combined with RAL group and PIs combined with NRTIs group; and a sub-analysis of the difference efficacy in ART-naïve patients and ART-experienced patients.
- Study Method
- Cost effectiveness, Diagnostic, Epidemiologic, Meta-analysis, Methodology, Prevention, Prognostic, Prospective meta-analysis (PMA), Qualitative synthesis, Systematic review
- Keyword
- HIV Infections; HIV Integrase Inhibitors; Humans; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium
- Contact
- Yinqiu Huang [email protected]
- Organisational Affiliation
- Chongqing Public Health Medical Center
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2017-11-28
- Registration Date
- 2017-12-21
- Anticipated Start Date
- 2017-10-25
- Anticipated Completion Date
- 2018-01-01
- Title Cn
- 拉替拉韦联合蛋白酶抑制剂简化方案在HIV-1患者中的疗效与安全性：一项随机对照试验的Meta分析
- Title En
- The efficacy and safety on simplification approach of Raltegravir combined with protease inhibitor in HIV-1 patients: a meta-analysis of RCTs
- Bilingual Status
- complete